Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Jul;60(1):89-90.
doi: 10.1111/apt.18032. Epub 2024 May 21.

Editorial: Unravelling real-world impact of second-line therapies in primary biliary cholangitis- Time to change our targets?

Guilherme Grossi Lopes Cançado  1   2   3
Affiliations
Editorial

Editorial: Unravelling real-world impact of second-line therapies in primary biliary cholangitis- Time to change our targets?

Guilherme Grossi Lopes Cançado. Aliment Pharmacol Ther. 2024 Jul.
No abstract available

PubMed Disclaimer

Comment in

Comment on

References

REFERENCES

    1. Levy C, Manns M, Hirschfield G. New treatment paradigms in primary biliary cholangitis. Clin Gastroenterol Hepatol. 2023;21(8):2076–2087. https://doi.org/10.1016/j.cgh.2023.02.005
    1. Webb GJ, Rana A, Hodson J, Akhtar MZ, Ferguson JW, Neuberger JM, et al. Twenty‐year comparative analysis of patients with autoimmune liver diseases on transplant waitlists. Clin Gastroenterol Hepatol. 2018;16(2):278–287.e7. https://doi.org/10.1016/j.cgh.2017.09.062
    1. Harms MH, van Buuren HR, Corpechot C, Thorburn D, Janssen HLA, Lindor KD, et al. Ursodeoxycholic acid therapy and liver transplant‐free survival in patients with primary biliary cholangitis. J Hepatol. 2019;71(2):357–365.
    1. Murillo Perez CF, Harms MH, Lindor KD, van Buuren HR, Hirschfield GM, Corpechot C, et al. GLOBAL PBC study group. Goals of treatment for improved survival in primary biliary cholangitis: treatment target should Be bilirubin within the Normal range and normalization of alkaline phosphatase. Am J Gastroenterol. 2020;115(7):1066–1074. https://doi.org/10.14309/ajg.0000000000000557
    1. Corpechot C, Lemoinne S, Soret PA, Hansen B, Hirschfield G, Gulamhusein A, et al. Global & ERN rare‐liver PBC study groups. Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: to what extent and under what conditions is normal alkaline phosphatase level associated with complication‐free survival gain? Hepatology. 2024;79(1):39–48. https://doi.org/10.1097/HEP.0000000000000529

MeSH terms

Substances

LinkOut - more resources